Which has the lower trailing P/E, ALNY or TEVA?

ALNY has the lower trailing P/E: ALNY trades at 45.17 and TEVA at 62.48. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, ALNY or TEVA?

Over the past five years, ALNY grew revenue faster — ALNY at a 47.53% CAGR versus TEVA at 1.19%.

Is ALNY or TEVA more profitable?

ALNY runs the higher net margin — ALNY at 16.82% versus TEVA at 4.08%.

How have ALNY and TEVA total returns compared?

Over the past 10 years, ALNY delivered 14.48% and TEVA delivered -2.67% annualized total return. Past performance doesn't predict future results.

Alnylam Pharmaceuticals, Inc. (ALNY) vs Teva Pharmaceutical Industries Limited (TEVA)

A side-by-side comparison of Alnylam Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Limited across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 3, 2026. Differences are shown without an overall score or investment verdict.

ALNY

Alnylam Pharmaceuticals, Inc.

$35.37B

$264.30HealthcareDelayed quote: Sep 3, 2026, 12:55 PM EDT

TEVA

Teva Pharmaceutical Industries Limited

$42.35B

$36.36HealthcareDelayed quote: Sep 3, 2026, 12:55 PM EDT

Total return — ALNY vs TEVA

growth of $100 · dividends reinvested · last 10y

ALNY +268.7% (+13.9%/yr)TEVA -22.7% (-2.5%/yr)ALNY compounded faster over this window

ALNY TEVA

ALNY vs TEVA: by the numbers

•TEVA is the larger company ($42.35B vs $35.37B market cap).
•ALNY trades at the lower trailing earnings multiple (45.17 vs 62.48 P/E), one valuation lens rather than an overall verdict.
•ALNY converts more revenue to profit (16.82% vs 4.08% net margin).
•ALNY grew revenue faster over the past five years (47.53% vs 1.19% CAGR).

Metrics side by side

Valuation

Metric	ALNY	TEVA
P/E ratio	45.17	62.48
Forward P/E	39.80	18.74
P/S ratio	7.69	2.56
P/B ratio	27.30	5.71
EV / EBITDA	34.65	19.35
FCF yield	1.47%	3.04%

Profitability

Metric	ALNY	TEVA
Gross margin	79.72%	52.47%
Operating margin	20.81%	11.45%
Net margin	16.82%	4.08%
ROE	59.67%	9.10%
ROIC	24.71%	6.79%

Growth (annualized)

Metric	ALNY	TEVA
Revenue CAGR (5Y)	47.53%	1.19%
FCF CAGR (5Y)	N/A	14.58%
Total return CAGR (5Y)	5.96%	31.54%

Frequently asked

Which has the lower trailing P/E, ALNY or TEVA?: ALNY has the lower trailing P/E: ALNY trades at 45.17 and TEVA at 62.48. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, ALNY or TEVA?: Over the past five years, ALNY grew revenue faster — ALNY at a 47.53% CAGR versus TEVA at 1.19%.
Is ALNY or TEVA more profitable?: ALNY runs the higher net margin — ALNY at 16.82% versus TEVA at 4.08%.
How have ALNY and TEVA total returns compared?: Over the past 10 years, ALNY delivered 14.48% and TEVA delivered -2.67% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ALNY analysis Full TEVA analysis Interactive comparison tool

Dig into the metrics

Alnylam Pharmaceuticals P/E ratio Teva Pharmaceutical Industries P/E ratio Alnylam Pharmaceuticals ROE Teva Pharmaceutical Industries ROE Alnylam Pharmaceuticals operating margin Teva Pharmaceutical Industries operating margin Alnylam Pharmaceuticals revenue growth Teva Pharmaceutical Industries revenue growth Alnylam Pharmaceuticals free cash flow Teva Pharmaceutical Industries free cash flow

Alnylam Pharmaceuticals & Teva Pharmaceutical Industries appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 3, 2026.